Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.46
MDCO's Cash to Debt is ranked higher than
70% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MDCO: 1.46 )
MDCO' s 10-Year Cash to Debt Range
Min: 1.1   Max: No Debt
Current: 1.46

Equity to Asset 0.50
MDCO's Equity to Asset is ranked higher than
60% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MDCO: 0.50 )
MDCO' s 10-Year Equity to Asset Range
Min: 0.49   Max: 0.89
Current: 0.5

0.49
0.89
Interest Coverage 0.85
MDCO's Interest Coverage is ranked lower than
53% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. MDCO: 0.85 )
MDCO' s 10-Year Interest Coverage Range
Min: 0.85   Max: 9999.99
Current: 0.85

0.85
9999.99
F-Score: 3
Z-Score: 1.72
M-Score: -2.55
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -6.35
MDCO's Operating margin (%) is ranked higher than
57% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. MDCO: -6.35 )
MDCO' s 10-Year Operating margin (%) Range
Min: -401.44   Max: 14.87
Current: -6.35

-401.44
14.87
Net-margin (%) -3.58
MDCO's Net-margin (%) is ranked higher than
57% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. MDCO: -3.58 )
MDCO' s 10-Year Net-margin (%) Range
Min: -385.2   Max: 29.79
Current: -3.58

-385.2
29.79
ROE (%) -2.86
MDCO's ROE (%) is ranked higher than
59% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. MDCO: -2.86 )
MDCO' s 10-Year ROE (%) Range
Min: -237.8   Max: 35
Current: -2.86

-237.8
35
ROA (%) -1.48
MDCO's ROA (%) is ranked higher than
60% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. MDCO: -1.48 )
MDCO' s 10-Year ROA (%) Range
Min: -183.56   Max: 24.65
Current: -1.48

-183.56
24.65
ROC (Joel Greenblatt) (%) -46.88
MDCO's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. MDCO: -46.88 )
MDCO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -16443.26   Max: 300.56
Current: -46.88

-16443.26
300.56
Revenue Growth (%) 10.10
MDCO's Revenue Growth (%) is ranked higher than
78% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. MDCO: 10.10 )
MDCO' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 88.9
Current: 10.1

0
88.9
EBITDA Growth (%) -7.90
MDCO's EBITDA Growth (%) is ranked higher than
61% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. MDCO: -7.90 )
MDCO' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -7.9
Current: -7.9

EPS Growth (%) -49.70
MDCO's EPS Growth (%) is ranked higher than
52% of the 674 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. MDCO: -49.70 )
MDCO' s 10-Year EPS Growth (%) Range
Min: 0   Max: 27.6
Current: -49.7

0
27.6
» MDCO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

MDCO Guru Trades in Q4 2013

Joel Greenblatt 13,990 sh (New)
Vanguard Health Care Fund 4,599,069 sh (+8.2%)
John Hussman 104,000 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Chuck Royce 4,599,842 sh (-4.91%)
George Soros 50,000 sh (-80%)
» More
Q1 2014

MDCO Guru Trades in Q1 2014

RS Investment Management 523,764 sh (New)
Jim Simons 53,042 sh (New)
Chuck Royce 6,115,200 sh (+32.94%)
Vanguard Health Care Fund 4,700,058 sh (+2.2%)
Joel Greenblatt Sold Out
George Soros Sold Out
John Hussman 67,000 sh (-35.58%)
» More
Q2 2014

MDCO Guru Trades in Q2 2014

George Soros 75,000 sh (New)
Joel Greenblatt 194,954 sh (New)
Chuck Royce 6,656,025 sh (+8.84%)
Vanguard Health Care Fund 4,700,058 sh (unchged)
Jim Simons Sold Out
John Hussman Sold Out
RS Investment Management 484,842 sh (-7.43%)
» More
Q3 2014

MDCO Guru Trades in Q3 2014

Vanguard Health Care Fund 4,762,730 sh (+1.33%)
Chuck Royce 6,729,175 sh (+1.1%)
George Soros Sold Out
RS Investment Management 477,466 sh (-1.52%)
Joel Greenblatt 24,009 sh (-87.68%)
» More
» Details

Insider Trades

Latest Guru Trades with MDCO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Reduce -87.68%0.06%$22.95 - $29.64 $ 27.046%24009
George Soros 2014-09-30 Sold Out 0.02%$22.95 - $29.64 $ 27.046%0
John Hussman 2014-06-30 Sold Out 0.14%$24.02 - $29.57 $ 27.041%0
Joel Greenblatt 2014-06-30 New Buy0.07%$24.02 - $29.57 $ 27.041%194954
George Soros 2014-06-30 New Buy0.02%$24.02 - $29.57 $ 27.041%75000
John Hussman 2014-03-31 Reduce -35.58%0.1%$27.9 - $40.39 $ 27.04-19%67000
George Soros 2014-03-31 Sold Out 0.02%$27.9 - $40.39 $ 27.04-19%0
Joel Greenblatt 2014-03-31 Sold Out 0.01%$27.9 - $40.39 $ 27.04-19%0
George Soros 2013-12-31 Reduce -80%0.07%$31.48 - $38.91 $ 27.04-24%50000
Joel Greenblatt 2013-12-31 New Buy0.01%$31.48 - $38.91 $ 27.04-24%13990
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.93
MDCO's P/B is ranked higher than
84% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. MDCO: 1.93 )
MDCO' s 10-Year P/B Range
Min: 1.14   Max: 11.31
Current: 1.93

1.14
11.31
P/S 2.47
MDCO's P/S is ranked higher than
81% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. MDCO: 2.47 )
MDCO' s 10-Year P/S Range
Min: 0.9   Max: 17.07
Current: 2.47

0.9
17.07
PFCF 29.08
MDCO's PFCF is ranked higher than
90% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. MDCO: 29.08 )
MDCO' s 10-Year PFCF Range
Min: 6.54   Max: 305.88
Current: 29.08

6.54
305.88
EV-to-EBIT -36.28
MDCO's EV-to-EBIT is ranked higher than
57% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. MDCO: -36.28 )
MDCO' s 10-Year EV-to-EBIT Range
Min: -824.5   Max: 790.2
Current: -36.28

-824.5
790.2
Shiller P/E 44.35
MDCO's Shiller P/E is ranked higher than
83% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. MDCO: 44.35 )
MDCO' s 10-Year Shiller P/E Range
Min: 25.91   Max: 748.5
Current: 44.35

25.91
748.5
Current Ratio 3.99
MDCO's Current Ratio is ranked higher than
82% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. MDCO: 3.99 )
MDCO' s 10-Year Current Ratio Range
Min: 0.75   Max: 10.09
Current: 3.99

0.75
10.09
Quick Ratio 3.47
MDCO's Quick Ratio is ranked higher than
82% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. MDCO: 3.47 )
MDCO' s 10-Year Quick Ratio Range
Min: 0.75   Max: 9.44
Current: 3.47

0.75
9.44

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.42
MDCO's Price/DCF (Projected) is ranked higher than
92% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. MDCO: 1.42 )
MDCO' s 10-Year Price/DCF (Projected) Range
Min: 0.84   Max: 11.15
Current: 1.42

0.84
11.15
Price/Median PS Value 0.82
MDCO's Price/Median PS Value is ranked higher than
92% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. MDCO: 0.82 )
MDCO' s 10-Year Price/Median PS Value Range
Min: 0.32   Max: 61.81
Current: 0.82

0.32
61.81
Earnings Yield (Greenblatt) -2.80
MDCO's Earnings Yield (Greenblatt) is ranked higher than
58% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MDCO: -2.80 )
MDCO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 15.2
Current: -2.8

0.1
15.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:MZN.Germany,
The Medicines Company was incorporated in Delaware on July 31, 1996. The Company is a global biopharmaceutical company focused on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on 3,000 acute and intensive care hospitals worldwide. The Company markets products including; Angiomax (bivalirudin), Recothrom Thrombin, topical (Recombinant), Cleviprex (clevidipine) injectable emulsion and Minocin IV (Minocycline for Injection). Angiomax is an intravenous direct thrombin inhibitor that is a peptide compound. Recothrom is a surgical hemostat that is applied topically during surgery to stop bleeding. Cleviprex is an intravenous small molecule calcium channel blocker. Minocin IV is an Tetracycline-class antibiotic used for treatment of bacterial infections caused by Acinetobacter species. The Company has a pipeline of acute and intensive care hospital products in development, including five registration stage product candidates; cangrelor, oritavancin, IONSYSTM (fentanyl iontophoretic transdermal system), Fibrocaps and RPX-602, and three research and development product candidates, MDCO-216, CarbavanceTM and ALN-PCSsc. In addition to these products and product candidates company also sells a ready-to-use formulation of Argatroban and have a portfolio of ten generic drugs, referred to as acute care generic products, that have the non-exclusive right to market in the United States. The Company is currently selling three of its acute care generic products, midazolam, ondansetron and rocuronium; and also co-promote the oral tablet antiplatelet medicine BRILINTA (ticagrelor) in the United States as part of global collaboration agreement with AstraZeneca LP and the Boston Scientific Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System, or the Promus PREMIER Stent System, in the United States under its co-promotion agreement with Boston Scientific Corporation, or BSX. It faces competition from pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. The Company and its customers are subject to extensive regulation by the federal government, and the governments of the states and foreign countries in which it may conduct its business. In addition to regulations in the United States, the Company is subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of its products.
» More Articles for MDCO

Headlines

Articles On GuruFocus.com
Chuck Royce Buys Stifel Financial, Tidewater, Alamos, Sells Kennametal, Gardner Denver, Gartner Apr 25 2013 
Weekly CFO Sells Highlight: BK, MDCO, EBAY, MS, PHMD Jan 27 2013 
Weekly CFO Sells Highlight: MDCO, SIG, VCI, PHMD, SNPS Jan 21 2013 
George Soros' Top Buys in the Last Quarter Dec 23 2011 
George Soros Buys Amazon.com Inc., Motorola Solutions, Sandisk, Sells Ralph Lauren, Dendreon, Lawson Nov 15 2011 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 100,000 Shares Mar 01 2011 
Medicines Company Reports Operating Results (10-Q) Nov 09 2010 
Medicines Company Reports Operating Results (10-Q) May 10 2010 
Medicines Company (MDCO) Chairman & CEO Clive Meanwell sells 181,500 Shares May 04 2010 
Medicines Company Reports Operating Results (10-Q) Nov 09 2009 

More From Our Partners
Alnylam Provides Pipeline Update, Growth Strategy - Analyst Blog Dec 15 2014 - ZACKS

More From Other Websites
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two... Dec 18 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two... Dec 18 2014
7:03 am The Medicines Co and SciClone Pharmaceuticals (SCLN)... Dec 18 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two... Dec 18 2014
The Medicines Company and SciClone Pharmaceuticals Establish Strategic Partnership for Two... Dec 18 2014
Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a... Dec 11 2014
Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a... Dec 11 2014
Alnylam and The Medicines Company Announce Initiation of Phase 1 Clinical Trial for ALN-PCSsc, a... Dec 11 2014
The Medicines Company to Participate in Oppenheimer 25th Annual Healthcare Conference Dec 08 2014
The Medicines Company Surges Amid Credit Suisse Upgrade Nov 20 2014
The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key... Nov 16 2014
The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key... Nov 16 2014
MEDICINES CO /DE Financials Nov 14 2014
The Medicines Company to Present New Data on Investigational Lipid-Modifying Agent MDCO-216 and... Nov 14 2014
The Medicines Company to Present New Data on Investigational Lipid-Modifying Agent MDCO-216 and... Nov 14 2014
The Medicines Company to Participate in Credit Suisse Healthcare Conference Nov 11 2014
The Medicines Company to Participate in Credit Suisse Healthcare Conference Nov 11 2014
10-Q for The Medicines Co. Nov 09 2014
MEDICINES CO /DE Files SEC form 10-Q, Quarterly Report Nov 07 2014
Health Economic Data on The Medicines Company’s Infectious Disease and Cardiology Portfolios to be... Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK